Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

Authors

  • Céline Phan
  • Nathalie Beneton
  • Juliette Delaunay
  • Ziad Reguiai
  • Claire Boulard
  • Anne-Claire Fougerousse
  • Elisa Cinotti
  • Marco Romanelli
  • Laure Mery-Bossard
  • Domitille Thomas-Beaulieu
  • Josiane Parier
  • François Maccari
  • Jean-Luc Perrot
  • Mireille Ruer-Mulard
  • Marie Bastien
  • Edouard Begon
  • Mahtab Samimi
  • Caroline Jacobzone
  • Nathalie Quiles-Tsimaratos
  • Vincent Descamps
  • Maud Steff
  • Paul Bilan
  • Annie Vermersch-Langlin
  • Mathilde Kemula
  • Emmanuelle Amazan
  • Ingrid Kupfer-Bessaguet
  • Anne-Caroline Cottencin
  • Francesca Prignano
  • Bulai Livideanu
  • Jeremy Gottlieb
  • Alain Beauchet
  • Emmanuel Mahé

DOI:

https://doi.org/10.2340/00015555-3678

Keywords:

psoriasis, anti-interleukin 17, elderly, safety, drug survival

Abstract

Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evalu?ated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ?65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n?=?4), oral candidiasis (n?=?3), and influenza-like illness (n?=?3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ??65 years.

Downloads

Download data is not yet available.

Published

2020-11-04

How to Cite

Phan, C., Beneton, N., Delaunay, J., Reguiai, Z., Boulard, C., Fougerousse, A.-C., Cinotti, E., Romanelli, M., Mery-Bossard, L., Thomas-Beaulieu, D., Parier, J., Maccari, F., Perrot, J.-L., Ruer-Mulard, M., Bastien, M., Begon, E., Samimi, M., Jacobzone, C., Quiles-Tsimaratos, N., Descamps, V., Steff, M., Bilan, P., Vermersch-Langlin, A., Kemula, M., Amazan, E., Kupfer-Bessaguet, I., Cottencin, A.-C., Prignano, F., Livideanu, B., Gottlieb, J., Beauchet, A., & Mahé, E. (2020). Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis. Acta Dermato-Venereologica, 100(18), 1–4. https://doi.org/10.2340/00015555-3678

Issue

Section

Articles